Ignite Creation Date:
2024-05-06 @ 7:09 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05918809
Status:
COMPLETED
Last Update Posted:
2023-06-26
First Post:
2023-06-16
Brief Title:
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma DLBCL Inpatient and Outpatient Settings
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma DLBCL Inpatient and Outpatient Settings
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A retrospective non-interventional cohort study was used to address the study objectives This study aimed to provide a better understanding of real-world healthcare resource utilization HRU and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell CAR-T therapy among patients with DLBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None